LncRNA SAMMSON Knockdown Inhibits the Malignancy of Glioblastoma Cells by Inactivation of the PI3K/Akt Pathway

[1]  Zhihong Wang,et al.  Long noncoding RNA SAMMSON promotes papillary thyroid carcinoma progression through p300/Sp1 axis and serves as a novel diagnostic and prognostic biomarker , 2020, IUBMB life.

[2]  Shanshan Liu,et al.  LncRNA SAMMSON overexpression distinguished glioblastoma patients from patients with diffuse neurosarcoidosis. , 2019, Neuroreport.

[3]  Chao Wu,et al.  MiR-148-3p inhibits growth of glioblastoma targeting DNA methyltransferase-1 (DNMT1). , 2019, Oncology research.

[4]  S. Shi,et al.  LncRNA TRG-AS1 promotes glioblastoma cell proliferation by competitively binding with miR-877-5p to regulate SUZ12 expression. , 2019, Pathology, research and practice.

[5]  Wenjing Zhou,et al.  Epithelial membrane protein 1 promotes glioblastoma progression through the PI3K/AKT/mTOR signaling pathway , 2019, Oncology reports.

[6]  Shouzhang Yang,et al.  LncRNA SAMMSON negatively regulates miR-9-3p in hepatocellular carcinoma cells and has prognostic values , 2019, Bioscience reports.

[7]  Yinghui Xu,et al.  AC016405.3, a novel long noncoding RNA, acts as a tumor suppressor through modulation of TET2 by microRNA‐19a‐5p sponging in glioblastoma , 2019, Cancer science.

[8]  J. Marine,et al.  SAMMSON fosters cancer cell fitness by enhancing concertedly mitochondrial and cytosolic translation , 2018, Nature Structural & Molecular Biology.

[9]  Bin Zhou,et al.  Knockdown of RWD domain containing 3 inhibits the malignant phenotypes of glioblastoma cells via inhibition of phosphoinositide 3-kinase/protein kinase B signaling. , 2018, Experimental and therapeutic medicine.

[10]  Jiuhong Kang,et al.  Long non-coding RNAs in glioma progression. , 2018, Cancer letters.

[11]  Krishna Prabhu,et al.  Primary spinal cord glioblastoma metastasizing to the cerebellum: A missed entity , 2018, Neurology India.

[12]  Liang Wang,et al.  SAMMSON drives the self-renewal of liver tumor initiating cells through EZH2-dependent Wnt/β-catenin activation , 2017, Oncotarget.

[13]  Jiang-hu Zhao,et al.  Analysis of long non-coding RNA expression profiles identifies novel lncRNA biomarkers in the tumorigenesis and malignant progression of gliomas , 2017, Oncotarget.

[14]  S. To,et al.  Recent advances in the use of PI3K inhibitors for glioblastoma multiforme: current preclinical and clinical development , 2017, Molecular Cancer.

[15]  Ziwei Wang,et al.  MicroRNA-22 suppresses the growth, migration and invasion of colorectal cancer cells through a Sp1 negative feedback loop , 2017, Oncotarget.

[16]  D. Reardon,et al.  The development of dendritic cell vaccine-based immunotherapies for glioblastoma , 2017, Seminars in Immunopathology.

[17]  M. Davis.  Glioblastoma: Overview of Disease and Treatment. , 2016, Clinical journal of oncology nursing.

[18]  Liu Cao,et al.  PI3K/Akt/mTOR signaling pathway and targeted therapy for glioblastoma , 2016, Oncotarget.

[19]  SAMMSON Long Noncoding RNA Is Essential for Melanoma Cell Viability. , 2016, Cancer discovery.

[20]  Maite Huarte.  The emerging role of lncRNAs in cancer , 2015, Nature Medicine.

[21]  R. F. Luco,et al.  A lncRNA regulates alternative splicing via establishment of a splicing-specific chromatin signature , 2015, Nature Structural &Molecular Biology.

[22]  L. Jia,et al.  miR-29b suppresses proliferation, migration, and invasion of tongue squamous cell carcinoma through PTEN-AKT signaling pathway by targeting Sp1. , 2014, Oral oncology.

[23]  Howard Y. Chang,et al.  Long noncoding RNAs in cell-fate programming and reprogramming. , 2014, Cell stem cell.

[24]  Z. Meng,et al.  Acetylated Sp1 inhibits PTEN expression through binding to PTEN core promoter and recruitment of HDAC1 and promotes cancer cell migration and invasion. , 2013, Carcinogenesis.

[25]  P. Wen,et al.  Current clinical development of PI3K pathway inhibitors in glioblastoma. , 2012, Neuro-oncology.

[26]  G. Riggins,et al.  Molecular targeting of glioblastoma: Drug discovery and therapies. , 2011, Trends in molecular medicine.

[27]  T. Hughes,et al.  Establishing legitimacy and function in the new transcriptome. , 2009, Briefings in functional genomics & proteomics.

[28]  W. Weiss,et al.  PI3K Signaling in Glioma—Animal Models and Therapeutic Challenges , 2009, Brain pathology.

[29]  A. Arcaro,et al.  The Phosphoinositide 3-Kinase Pathway in Human Cancer: Genetic Alterations and Therapeutic Implications , 2007, Current genomics.

[30]  Lewis C. Cantley,et al.  AKT/PKB Signaling: Navigating Downstream , 2007, Cell.

[31]  Chuanshu Huang,et al.  The PI3K/Akt pathway and its downstream transcriptional factors as targets for chemoprevention. , 2007, Current cancer drug targets.

[32]  G. Fuller,et al.  Analysis of the activation status of Akt, NFκB, and Stat3 in human diffuse gliomas , 2004, Laboratory Investigation.

[33]  Alona Muzikansky,et al.  The prognostic significance of phosphatidylinositol 3-kinase pathway activation in human gliomas. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[34]  T. Yamasaki,et al.  Synergistic augmentation of antimicrotubule agent-induced cytotoxicity by a phosphoinositide 3-kinase inhibitor in human malignant glioma cells. , 2003, Cancer research.